Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Lexicon Pharmaceuticals Is Down 11% Today

TheMotleyFool

0 0

Why Lexicon Pharmaceuticals Is Down 11% Today

After Lexicon Pharmaceuticals (NASDAQ: LXRX) announced yesterday the publication of phase 3 results for its lead diabetes drug, sotagliflozin, in the New England Journal of Medicine, its shares are losing 11% of their value at 11:45 a.m. EDT.

Sotagliflozin is a novel diabetes drug that attempts to improve glycemic control by targeting both SGLT1 and SGLT2 for the first time.

IMAGE SOURCE: GETTY IMAGES.

Source: Fool.com